Decibel Therapeutics, Inc.

DBTXNASDAQHealthcare

$4.91

$-0.04(-0.81%)

Market Cap$123373079

P/E Ratio—

52W High$5.4

52W Low$1.61

Avg Volume247K

Open$4.92

Beta-0.40

Earnings Financials Revenue

Decibel Therapeutics, Inc. (DBTX) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

DBTX · earnings · updated Jun 8, 2026

Latest Earnings

Q3 FY2023Report Date: Aug 11, 2023

EPS Actual

$0.73

Est. $0.57 · +28.1%

Revenue

—

Est. $0.00B

Fiscal Period

Q3 FY2023

FY ends December

Report Date

Aug 11, 2023

After Market Close

▲ Beat EPS🔥 8-Quarter EPS Beat Streak

DBTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$0.09

Rev. $41.31B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$0.09

Rev. Est.$41.31B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2024	Aug 9, 2024	—	—	—	—	—	—
◌ Q2 FY2024	May 13, 2024	—	—	—	—	—	—
◌ Q1 FY2024	Mar 12, 2024	—	—	—	—	—	—
◌ Q4 FY2023	Nov 8, 2023	-$0.61	—	—	—	—	—
▲ Q3 FY2023	Aug 11, 2023	$0.57	$0.73	+28.1%	—	$0.00B	—
▲ Q2 FY2023	May 15, 2023	$0.48	$0.53	+10.4%	—	$0.00B	—
▲ Q1 FY2023	Mar 14, 2023	$0.20	$0.63	+215.0%	—	$0.01B	—
— Q4 FY2022	Nov 9, 2022	$0.64	$0.64	+0.0%	—	—	—

Q3 FY2024

Aug 9, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2024

May 13, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2024

Mar 12, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2023

Nov 8, 2023

EPS Actual

—

EPS Est.

-$0.61

EPS Surpr.

—

Revenue

—

Q3 FY2023

Aug 11, 2023Beat

EPS Actual

$0.73

EPS Est.

$0.57

EPS Surpr.

+28.1%

Revenue

—

Q2 FY2023

May 15, 2023Beat

EPS Actual

$0.53

EPS Est.

$0.48

EPS Surpr.

+10.4%

Revenue

—

Q1 FY2023

Mar 14, 2023Beat

EPS Actual

$0.63

EPS Est.

$0.20

EPS Surpr.

+215.0%

Revenue

—

Q4 FY2022

Nov 9, 2022

EPS Actual

$0.64

EPS Est.

$0.64

EPS Surpr.

+0.0%

Revenue

—

No analyst estimates available for DBTX.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q3 FY2023	Aug 11, 2023	+28.1%	$5.16	$5.11	-0.97%
▲ Q2 FY2023	May 15, 2023	+10.4%	$3.61	$3.78	+4.71%
▲ Q1 FY2023	Mar 14, 2023	+215.0%	$4.07	$4.08	+0.25%
▲ Q4 FY2022	Nov 9, 2022	+0.0%	$3.28	$3.11	-5.18%
▲ Q3 FY2022	Aug 10, 2022	+25.9%	$4.08	$4.29	+5.15%
▲ Q2 FY2022	May 12, 2022	+3.7%	$2.04	$2.07	+1.47%
▲ Q1 FY2022	Mar 18, 2022	+19.5%	$3.00	$3.10	+3.33%
▲ Q4 FY2021	Nov 10, 2021	+65.0%	$7.52	$7.50	-0.27%

Q3 FY2023-0.97%

Report Date

Aug 11, 2023

EPS Beat/Miss

+28.1%

Price Before

$5.16

Price After

$5.11

Q2 FY2023+4.71%

Report Date

May 15, 2023

EPS Beat/Miss

+10.4%

Price Before

$3.61

Price After

$3.78

Q1 FY2023+0.25%

Report Date

Mar 14, 2023

EPS Beat/Miss

+215.0%

Price Before

$4.07

Price After

$4.08

Q4 FY2022-5.18%

Report Date

Nov 9, 2022

EPS Beat/Miss

+0.0%

Price Before

$3.28

Price After

$3.11

Q3 FY2022+5.15%

Report Date

Aug 10, 2022

EPS Beat/Miss

+25.9%

Price Before

$4.08

Price After

$4.29

Q2 FY2022+1.47%

Report Date

May 12, 2022

EPS Beat/Miss

+3.7%

Price Before

$2.04

Price After

$2.07

Q1 FY2022+3.33%

Report Date

Mar 18, 2022

EPS Beat/Miss

+19.5%

Price Before

$3.00

Price After

$3.10

Q4 FY2021-0.27%

Report Date

Nov 10, 2021

EPS Beat/Miss

+65.0%

Price Before

$7.52

Price After

$7.50

Avg Beat Reaction+1.06%

Beat Rate8 / 8 quarters

Largest Move-5.18% (Q4 FY2022)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Decibel Therapeutics, Inc. (DBTX) most recently reported earnings on August 11, 2023 for Q3 FY2023, posting EPS of $0.73 — beating the analyst consensus of $0.57 by +28.1%. DBTX has beaten EPS estimates for 8 consecutive quarters. The next DBTX earnings date is expected around September 1, 2026.

Each quarter, investors track DBTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DBTX revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

DBTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

DBTX earnings · 5 questions

Decibel Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. DBTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DBTX historically reports after market close (AMC).

DBTX earnings datewhen is DBTX earningsDBTX next earnings datewhen does DBTX report earningsDBTX earnings calendar

▸ Source: FMP · Decibel Therapeutics, Inc. SEC filings · US GAAP · Decibel Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026